Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2008)
14 slides from Cogstate's shareholder meeting presentation, Oct 23, 2008
Slide 1: Annual General Meeting
For personal use only Annual General Meeting 23 October 2008 www.cogstate.com
Slide 2: Martyn Myer, Chairman
For personal use only Martyn Myer Chairman www.cogstate.com
Slide 3: Overview – FY08
OVERVIEW – FY08 The Numbers: For personal use only • 61% revenue growth for FY08 • A$0.5m positive cash flow from operations for H2 FY08 • 162% growth in the value of contracts signed during FY08 (A$5m) • 13 phase II contracts signed during FY08 (FY07 = nil) • 37 contracts signed FY08 (FY07 = 17) •
Slide 4: Increased Sales Focus
INCREASED SALES FOCUS • Increase in senior science / sales staff For personal use only – Pre existing science / sales staff: • Prof. Paul Maruff, Melbourne based neuropsychologist • Prof. Peter Snyder, US based consultant to CogState, formerly Pfizer, now Brown University – Dr John Harrison joined i
Slide 5: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer www.cogstate.com
Slide 6: UBC Partnership
UBC PARTNERSHIP • UBC agreement signed July 2008 For personal use only – Initial 15% holding in CogState from private placement and underwriting of Rights Issue – Allows CogState to build a comprehensive service offering, especially for larger Phase II and III studies – Unmatched operational capabil
Slide 7: Q1 FY09
Q1 FY09 • Q1 FY09 result – first operating profit For personal use only – A$1.99m revenue for Q1 • A$0.5 million from contracts on hand at 1 July 2008 • A$1.5 million from contracts signed during Q1 – A$5m revenue for the trailing twelve months – A$0.5m cash inflow from operations for the trailing t
Slide 8: Q1 FY09 Summary of clinical trial contracts
Q1 FY09 Summary of clinical trial contracts: For personal use only – A$3.5m contracts signed since 1 July 2008 (A$1 = US$0.70) • Includes A$1.4m phase III schizophrenia trial • 4 x Phase II studies with average value of A$0.27m Phase of FY07 FY08 FY09 Trial Q1 Phase I 11 19 7 Phase II 0 13 4 Phase I
Slide 9: September - Summary Balance Sheet
30 September - Summary Balance Sheet Includes impact of capital raising from Rights Issue and Private Placement For personal use only 30 June 08 30 Sept 08 Movement Cash and cash 1,048,207 1,946,487 898,280 investments Trade debtors 612,778 1,490,539 877,761 Other assets 236,971 324,968 87,997 Fixed
Slide 10: Sales contracts driving revenue growth
Sales contracts driving revenue growth Recognised Sales Revenue, By Quarter For personal use only 2,250 2,000 1,750 $'000 1,500 1,250 1,000 750 500 250 - www.cogstate.com
Slide 11: Trailing Twelve Months Sales Revenue
CogState ClinicalTrials: building a profitable business Trailing Twelve Months Sales Revenue For personal use only 6,000 5,000 4,000 Sales Revenue $'000 3,000 2,000 1,000 - Dec-04 Mar-05 Jun-05 Sep-05 Dec-05 Mar-06 Jun-06 Sep-06 Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Mar-08 Jun-08 Sep-08 12 months ended
Slide 12: Trailing Twelve Months Operating Cash Flow
CogState ClinicalTrials: building a profitable business Trailing Twelve Months Operating Cash Flow For personal use only 1,500,000 1,000,000 500,000 Debtors movement - Jun-06 Sep-06 Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Mar-08 Jun-08 Sep-08 Cash flow from operations Cash flow from operations + debtors
Slide 13: FY09 Outlook
FY09 Outlook • FY09 Q2 For personal use only – Sales revenue of at least $1.5 million – At this level, expect operating break even for Q2 • FY09 H1 – Expect to record first operating profit for the first half • At this time, we are not issuing profit guidance for the second half of the financial yea
Slide 14: Brad O'Connor, Chief Executive Officer
For personal use only Brad O’Connor Chief Executive Officer CogState Ph: 03 9664 1300 boconnor@cogstate.com www.cogstate.com